NAS
HRTX icon

Nicolet Advisory Services’s Heron Therapeutics HRTX Stock Holding History

Nicolet Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$23.8K Hold
16,000
– – ﹤0.01% 421
2025
Q3 		$21.1K Hold
16,000
– – ﹤0.01% 414
2025
Q2 		$27K Hold
16,000
– – ﹤0.01% 407
2025
Q1 		$29.1K Hold
16,000
– – ﹤0.01% 379
2024
Q4 		$24.8K Buy
+16,000
New +$25.9K ﹤0.01% 380

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Nicolet Advisory Services's HRTX Position: Q4 2025 in Review

Nicolet Advisory Services held its Heron Therapeutics (HRTX) position steady in Q4 2025 at 16,000 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

Nicolet Advisory Services first reported a position in HRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $29.1K in Q1 2025. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Nicolet Advisory Services held 16,000 shares of Heron Therapeutics worth $23.8K as of Q4 2025.
  • Nicolet Advisory Services left its Heron Therapeutics share count unchanged in Q4 2025.
  • Heron Therapeutics made up ﹤0.01% of Nicolet Advisory Services's portfolio in Q4 2025, its #421 holding.
  • Nicolet Advisory Services first reported a position in Heron Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Nicolet Advisory Services's Heron Therapeutics position peaked at $29.1K in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Nicolet Advisory Services's 13F filing for Q4 2025, filed 13 Feb 2026.